Nervgen Pharma Corp. has appointed Neil Klompas to the company’s board of directors. “We are very pleased that Neil is joining our board at a pivotal time as we prepare for future growth,” said Glenn Ives, Nervgen’s chairman. “His substantial expertise of over two decades in U.S. and Canadian finance, licensing, and mergers and acquisitions… Continue reading NERVGEN PHARMA APPOINTS NEIL KLOMPAS TO BOARD OF DIRECTORS

Unidoc Health Corp. has deployed an AI-equipped (artificial intelligence) H3 Health Cube to Okhmatdyt, Ukraine’s largest children’s hospital. This deployment follows a recent missile attack and is part of the previously announced purchase order through HP Inc., facilitated by the Hope Ukraine Foundation. The cube currently being fabricated by Unidoc and is expected to ship… Continue reading UNIDOC AI H3 CUBE SUPPLIED THROUGH HP INC. TO BE DEPLOYED TO UKRAINE’S LARGEST CHILDREN’S HOSPITAL

Rakovina Therapeutics Inc., further to the news releases dated May 23, 2024, and June 20, 2024, to accommodate additional indications of interest, will upsize the previously announced private placement of $2.0-million to $2.3-million, subject to TSX Venture Exchange ) approval. The terms of the private placement otherwise remain unchanged. The company now anticipates closing the… Continue reading RAKOVINA THERAPEUTICS ANNOUNCES SECOND UPSIZING OF PRIVATE PLACEMENT

VANCOUVER, BC / ACCESSWIRE / July 17, 2024 / BioNxt Solutions Inc. (“BioNxt” or the “Company“) (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that it has signed a statement of work (“SOW”) with a German-based international contract research, development, and manufacturing organization (the “CRDMO”). The SOW is focused on the Company’s flagship Cladribine oral dissolvable film (“ODF”) development… Continue reading BioNxt Signs Statement of Work with International Contract Research, Development, And Manufacturing Organization for Cladribine ODF Development

VANCOUVER, BC and MADISON, Wis., July 17, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys”) and SpayVac-for-Wildlife, Inc. (“SpayVac”) jointly announce that SpayVac has partnered with the Elephant and Wildlife Clinic, Faculty of Veterinary Medicine at Chiang Mai University in Thailand to test SpayVac®, a long-lasting, single-dose contraceptive vaccine, in captive Asian elephants. SpayVac utilizes a… Continue reading BIOVAXYS AND SPAYVAC-FOR-WILDLIFE, INC. ANNOUNCE LAUNCH OF TRIAL TO TEST IMMUNOCONTRACEPTION IN ASIAN ELEPHANTS

Inside the state-of-the-art $43 million Veterans Affairs facility in Orlando, Florida, named the National Center for Simulation Validation, Evaluation, and Testing (SimVET), there are no real patients—only simulated ones. This 53,000-square-foot center is the main hub where VA healthcare workers practice procedures and test new technologies without risking patient safety. Opened in 2016, SimVET exemplifies… Continue reading Inside the $43 million Veterans Affairs simulation hospital where doctors are piloting new tech

The job market may have cooled, but there are still more job openings nationwide than people available to fill them, making qualified workers a precious commodity. Companies seeking to attract great employees often look for states offering a high quality of life. However, some states do not measure up in this regard. CNBC’s America’s Top… Continue reading These are America’s 10 worst states for quality of life in 2024

The article discusses the evolving landscape of obesity and diabetes treatment, focusing on the pharmaceutical industry’s shift towards developing oral medications as alternatives to existing injectable drugs. Currently, popular GLP-1 agonist drugs like Novo Nordisk’s Wegovy and Eli Lilly’s Ozempic dominate the market despite their high costs and weekly injection requirements. However, new advancements aim… Continue reading Healthy Returns: Drugmakers are racing to develop more convenient weight loss pills

Pfizer announced plans to advance its once-daily version of the weight loss pill danuglipron following promising results from ongoing early-stage studies. The company identified a formulation with a favorable safety profile and positive physiological responses. Further early-stage trials are slated for the second half of the year to determine the optimal dosage, with results expected… Continue reading Pfizer moves forward with once-daily version of weight loss pill after setbacks

VANCOUVER, British Columbia, July 09, 2024 (GLOBE NEWSWIRE) — Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “Company” or “Treatment AI”) is pleased to provide a general corporate update. Treatment AI has been working diligently through Q1 and Q2 to ensure continued evolution of its platform (Global Library of Medicine or GLM) and… Continue reading Treatment.com AI Provides Latest Corporate Update

VANCOUVER, BC / ACCESSWIRE / July 9, 2024 / BioNxt Solutions Inc. (“BioNxt” or the “Company“) (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that it has signed a master services agreement (“MSA”) with a German-based international contract research, development, and manufacturing organization (the “CRDMO”). The MSA will serve as the foundation for BioNxt’s future product development, particularly its… Continue reading BioNxt Signs Master Services Agreement with International Contract Research, Development, and Manufacturing Organization

Novo Nordisk investors remained largely unfazed by a recent Harvard Medical School study linking weight loss drugs containing semaglutide to an increased risk of a rare eye condition. The study suggested that patients prescribed semaglutide, found in drugs like Ozempic and Wegovy, faced higher odds of developing nonarteritic anterior ischemic optic neuropathy (NAION), which can… Continue reading Novo Nordisk shares shrug off concerns over study linking weight loss drugs to rare eye condition